SPONSOR

Fudan University

Total Trials

Recruiting

Phases

Phase 2, Phase 3

Conditions studied: Esophageal Cancer Large B-Cell Lymphoma Lung Cancer (NSCLC)Lymph Node Dissection Triple-negative Breast Cancer Breast Cancer Perioperative Immunotherapy Limited Stage Lung Small Cell Carcinoma Resectable Small Cell Lung Cancer Ovarian Cancer

Fudan University is a clinical research sponsor with 16 registered studies on ClinicalTrials.gov, of which 16 are actively recruiting participants. Research covers conditions including Esophageal Cancer, Large B-Cell Lymphoma, Lung Cancer (NSCLC), Lymph Node Dissection.

The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Fudan University

How many clinical trials has Fudan University sponsored?

ClinicalMetric currently tracks 16 clinical trials sponsored by Fudan University, of which 16 are actively recruiting participants. These trials cover conditions including Esophageal Cancer, Large B-Cell Lymphoma, Lung Cancer (NSCLC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Fudan University research focus on?

Fudan University clinical trials span Esophageal Cancer, Large B-Cell Lymphoma, Lung Cancer (NSCLC), Lymph Node Dissection, Triple-negative Breast Cancer, and additional conditions. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Fudan University clinical trial?

To participate in a Fudan University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fudan University trials with current recruitment status updated daily.

Fudan University

Frequently Asked Questions — Fudan University

Clinical Trials by Fudan University

Precision Palliative Care for Patients With Advanced Esophageal Cancer

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer

Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Novel Therapy Target in Metastatic Prostate Cancer

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer